African startups take on medicine access gaps with smarter supply chains
The session brought together African entrepreneurs who are working to improve access to medicine, patient safety, and supply chain systems. It was moderated by Stella Kivila, Director of Healthtech Strategy & Impact at Salient Advisory, a firm tracking over 1,000 healthtech start-ups across Africa.
'We are seeing a new generation of African entrepreneurs tackling one of the continent's most pressing problems: fragmented and inefficient medicine supply chains,' said Kivila.
The cost of fragmentation
Public healthcare distribution systems across Africa are often overburdened, with many consumers relying on fragmented private supply chains. According to Kivila, this can add as much as 60% to the final price of medicines. "Patients are left with little guarantee of quality or availability, and there is a significant risk of counterfeit and substandard products entering the system," she said.
Two start-ups – Dawa Mkononi from Tanzania and Meditect from Côte d'Ivoire – shared how they are using technology, data and new models to improve healthcare delivery.
Dawa Mkononi: "Medicine in the palm of your hand"
Dr Joseph Paul, a medical doctor and software engineer, founded Dawa Mkononi after a pivotal experience in a rural Tanzanian village. "While assisting a mother during childbirth, the essential drug needed to accelerate labour was unavailable. Six hours later, the family returned with a medicine that sadly proved ineffective. It was likely a counterfeit."
Paul developed a digital platform and distribution system to deliver safe, verified medicines to pharmacies, clinics and hospitals, supported by inventory management and demand forecasting. In urban areas, delivery takes a few hours. The platform also offers credit financing.
"Our mission is to make medicine accessible, affordable and safe, through data-driven supply chains," Paul said. The company has reached over 1,000 pharmacies, served more than 500,000 patients, and facilitated over $1m in credit. It is currently growing fourfold annually.
Meditect: Restoring trust in medicines
For Dr Arnaud Pourredon, founder of Meditect, the turning point also came from a moment in clinical care. 'I couldn't buy malaria treatment for a three-year-old child. That's when I knew we had to fix the system,' he said.
Meditect provides digital tools that support drug traceability, supply chain visibility and pharmacy management, with a focus on Francophone Africa. "By improving access to quality medicine and enhancing transparency, we can increase life expectancy in Africa by 10 years," Pourredon said.
The platform supports thousands of healthcare professionals and aims to help leapfrog infrastructure gaps using technology.
i3: A new model for supporting innovators
Both Dawa Mkononi and Meditect are part of the Investing in Innovation (i3) programme, launched in 2022 to connect African health supply chain innovators with donors, governments and the private sector. The initiative has provided $3m in grant funding to 60 start-ups in 18 countries.
Rather than acting as a traditional accelerator, i3 offers tailored support and market access, backed by partners including the Gates Foundation, MSD, Cencora, Endless Foundation, HELP Logistics, and Sanofi's Global Health Unit.
"Africa doesn't lack ingenuity. It lacks systems to support and scale it," said Kivila. "That's what we're fixing with i3."
Locally led systems for Africa and beyond
The panel was part of the 47th annual Sapics Conference, attended by more than 700 supply chain professionals from across Africa and the world.
As Kivila concluded: "Africa's healthcare future does not have to be imported. It is being built here – by Africans, for Africans, and increasingly, for the world."
All rights reserved. © 2022. Bizcommunity.com Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
11 hours ago
- Khaleej Times
Burjeel net profit surges 128.9% in the second quarter
Burjeel Holdings delivered strong top-line growth of 18.7 per cent to Dh1,403 million in Q2'25, driven by a 12.1 per cent increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, the super-specialty healthcare services provider announced on Thursday. Net profit surged 128.9 per cent to Dh148 million in Q2'25, reflecting margin expansion, enhanced operating leverage, and asset optimisation. In H1'25, net profit rose 10.6 per cent to Dh187 million. Ebitda rose 59.4 per cent to Dh306 million in Q2'25, fuelled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes Dh72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The Ebitda margin expanded 5.6 p.p. to 21.8 per cent. In H1'25, Ebitda increased 14.2 per cent to Dh487 million, with a margin of 18.2 per cent. Revenue in H1'25 rose 12.2 per cent to Dh2,677 million, with total patient visits reaching 3.4 million. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent), cardiology (+16 per cent), and gastroenterology (+13 per cent). John Sunil, CEO of Burjeel Holdings, was optimistic about maintaining strong momentum through the second half. 'We continue to target mid-teens revenue growth for the year, supported by the ramp-up of new assets and strategic expansion in both the UAE and Saudi Arabia,' he said. A key focus is making sure that Burjeel's new centres and services are launched smoothly and begin contributing at full potential. 'Major investments in specialised care, technology, and new geographies do not translate into financial returns overnight. But the strategy we have been executing is absolutely the right one, and this quarter's results are a clear example of how our growth strategy and investments in complex care are beginning to yield measurable financial results,' Sunil said. Inpatient footfall rose 17.7 per cent in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. Outpatient footfall grew 12.0 per cent in Q2'25, accelerating from 5.2 per cent in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25, enabled by optimised hiring and scaling of clinical teams. The Hospitals segment continued to drive group performance, contributing 89 per cent of total revenue in Q2'25. Revenue grew 17.3 per cent to Dh1,245 million, supported by strong growth in patient volumes and sustained demand for complex care services. Segment Ebitda rose by 40.6 per cent, led by strong performance across key hospitals. Operating cash flow increased 8.1 per cent YoY in H1'25, driven by improved operational performance and disciplined working capital management. Maintenance capex remained in line with guidance, while growth capex totalled Dh403 million, driven by strategic M&A activities and ongoing network expansion. Free cash flow conversion improved to 54 per cent in H1'25. In May 2025, the Group declared a full-year dividend of Dh170 million for FY2024, representing 47 per cent of net profit. Cost control was a key contributor to the company's performance. 'Even with 143 new physicians onboarded over the past year, we were able to optimise personnel costs through better workforce planning and clinical scheduling. We also brought overheads down by 7 per cent quarter-on-quarter and over 13 per cent compared to Q4, by normalising spend and embedding stronger cost discipline across the group. These efforts, alongside strong top-line growth, drove a significant improvement in margins,' Sunil said. The Trust Fertility Center, now the largest in the UAE, broke even within six months and has served over 1,800 unique patients with outcomes well above global benchmarks. 'It plays a key role in our women's health platform and aligns with the UAE's national fertility strategy. Looking ahead, we're replicating this model in Al Ain and Dubai, while continuing to invest in precision medicine, AI-enabled care, and complex specialties,' Sunil said.
Arabian Business
12 hours ago
- Arabian Business
Burjeel bounces back with strong Q2 numbers after March lows
With a rise in its number of inpatient and outpatient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, Burjeel Holdings announced an impressive 128.9 per cent jump in net profit to AED 148 million (US$40.3 million) in the second quarter of 2025. Net profit for the first six months rose 10.6 per cent to AED 187 million (US$50.9 million). The rise in net profit for Q2 was also due to a decline in footfall for the month of March, which was attributed by the company to the Holy Month of Ramadan. Those numbers were overwhelmingly reversed in the second quarter of the year, as inpatient footfall rose 17.7 per cent, and outpatient footfall grew 12 per cent. Revenue grew 18.7 per cent to AED 1,403 million (US$382 million) in Q2'25, while revenue for the first six months rose 12.2 per cent to AED 2,677 million (US$728.9 million). Total patient visits reached 3.4 million. The Group performed 22,930 surgeries, up 18.7 per cent. Bed occupancy improved to 69 per cent, up from 65 per cent a year ago. Inpatient volumes rose 14.6 per cent over the first half. The outpatient footfall was driven by primary care and physiotherapy centers, along with strong demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25. This was made possible by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded good gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent) and cardiology (+16 per cent). John Sunil, Chief Executive Officer of Burjeel Holdings, commented: 'The second quarter delivered exceptionally strong results, with 19 per cent revenue growth driven by a 12 per cent increase in patient footfall and improved yield. EBITDA rose by 59 per cent, accompanied by a margin uplift to 22 per cent. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel Holdings' resilience and long-term sustainable growth. 'These results reflect tangible progress in key operational areas such as physician manpower optimisation, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in high-value services and next-generation care facilities to support long-term momentum. 'We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE's largest private network, featuring new cancer clinics and cell and gene therapy capabilities.' EBITDA rose 59.4 per cent to AED 306 million (US$83.3 million) in Q2'25, fueled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes AED 72 million (US$19.6 million) in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 points to 21.8 per cent. In H1'25, EBITDA increased 14.2 per cent to AED 487 million (US$132.6 million). 'Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported by rising demand for complex care and a growing population. Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value,' Sunil added. 'Net profit growth of 129 per cent in the reporting quarter reinforces this trajectory and strengthens the foundation for consistent shareholder returns.'
Zawya
16 hours ago
- Zawya
Egypt's UHIA generates $1bln revenues in FY2024/25
Arab Finance: Egypt's Universal Health Insurance Authority (UHIA) generated revenues valued at EGP 69 billion in the fiscal year (FY) 2024/2025, marking a 49% year-on-year (YoY) leap from EGP 46.6 billion, according to a statement. During its 94th regular meeting, the authority's board of directors reviewed its preliminary financial position for the period from July 2024 to June 2025. Total spending for FY2024/25 hiked by 71% to EGP 17 billion from EGP 10 billion in FY2023/2024. The authority also achieved a surplus of approximately EGP 52.1 billion in FY2024/2025, an annual growth of 43% from EGP 36.4 billion. Meanwhile, total accumulated various allocations increased by 25% YoY to EGP 10.9 billion. The authority's total assets stood at EGP 187 billion at the end of June 2025. © 2025 All Rights Reserved Arab Finance For Information Technology Provided by SyndiGate Media Inc. (
